Read the full Auctus – BioConnnexUS article on Medical Product Outsourcing
Among the 30 largest medtech companies, more than 60 percent attribute their revenue growth to M&A.
Medtech companies that selectively choose not to take advantage of M&A find it challenging to scale — and many of the smaller companies are forced to focus on organic growth due to balance sheet capacity issues, while large corporate giants turn to dealmakers around the world to continue scaling and discover more opportunities for deal making for growth.
As the increasing search for innovation continues, Medtech companies hoping to expand globally should take advantage of three key macro drivers for cross-border M&A.
Auctus-BioConnnexUS, a strategic partnership between multifaceted investment bank Auctus Capital Partners and boutique life sciences advisory firm BioConnexUS, is committed to leveraging its resources and provide services to help emerging growth Med-Tech companies globalize their technologies, raise capital and support sell side M&A transactions. Auctus-BioConnexUS’s main services include investment banking, capital fundraising, market-entry and localization strategies.